Source: Faith Leonard and Gretchen Jacobson, “What Does the Decline in Medicare Part D Plan Availability Mean for ...
The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together ...
Ascentage Pharma's first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in ...
Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the nomination of CID-165, a first-in-class, ...
In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Andrew Willett discussed the path that led him to Lundbeck and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results